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PCardiovascular Effects of Tobacco
emodynamic and Autonomic Effects of
mokeless Tobacco in Healthy Young Men
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OBJECTIVES The aim of this study was to investigate the acute hemodynamic and autonomic effects of
smokeless tobacco.
BACKGROUND Smokeless tobacco use is increasing. Its cardiovascular effects are not well understood.
METHODS Sixteen healthy, male, habitual snuff tobacco users (aged 22  1 year) were studied, using a
randomized, double-blind, placebo-controlled, crossover design with two separate experi-
mental sessions: placebo and tobacco. Muscle sympathetic nerve activity (MSNA), electro-
cardiogram, blood pressure, calf blood flow, nicotine, and catecholamines were measured.
RESULTS Snuff tobacco increased plasma nicotine from 2.8  0.5 ng/ml to 10.4  1.1 ng/ml. Mean
blood pressure increased by 10  1 mm Hg, and heart rate increased by 16  2 beats/min.
Peripheral vascular resistance, MSNA, and norepinephrine concentration did not change
with tobacco, but epinephrine increased by 50%.
CONCLUSIONS Oral snuff tobacco increases heart rate, blood pressure, and epinephrine. Despite the increase
in blood pressure, there is no decrease in either MSNA or peripheral vascular resistance.
Smokeless tobacco is a powerful autonomic and hemodynamic stimulus. Catecholamine
release from the adrenal medulla likely contributes to this response. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.0562005;45:910–4) © 2005 by the American College of Cardiology Foundation
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1ver 5,000,000 adults and 750,000 adolescents use
mokeless tobacco in the U.S. (1). The prevalence is
ncreased in young males, especially athletes (2,3). In
ontrast to cigarette smoking, the cardiovascular effects of
mokeless tobacco are not well understood. Previous studies
eported conflicting results regarding cardiovascular risk in
ersons using smokeless tobacco. Case-control studies sug-
est no increased risk of myocardial infarction or stroke in
egular snuff users (4,5), but a tendency towards increased
isk of fatal myocardial infarction (4). A prospective study
inked smokeless tobacco to higher risk of cardiovascular
eath (6), although another study found no association
etween smokeless tobacco and cardiovascular mortality (7).
Similarly, studies investigating effects of smokeless to-
acco on rest blood pressure (BP) (reviewed by Asplund [8])
re inconsistent, noting either an increase (9–12) or no
ignificant change (13) in blood pressure after acute expo-
ure to smokeless tobacco. Many previous studies were not
lacebo-controlled and/or were not blinded; mechanisms
nderlying any acute responses to spit tobacco were not
nvestigated.
Effects of chewing tobacco on vascular resistance and
ympathetic nerve traffic in humans have never been studied.
sing a double-blind, randomized, placebo-controlled,
rossover design, we investigated the acute effects of snuff
From the *Mayo Clinic, Rochester, Minnesota; and †Medical University of
dansk, Gdansk, Poland. Financial support: NIH HL-61560, HL-65176, HL-
0302, MO1-RR00585, and 3F05-TW-05200.e
Manuscript received July 16, 2004; revised manuscript received November 17,
004, accepted November 29, 2004.obacco on heart rate (HR), BP, peripheral vascular resis-
ance, muscle sympathetic nerve activity (MSNA), and
atecholamines in healthy male habitual tobacco users.
ETHODS
tudy subjects. We studied 16 healthy, male, habitual spit
obacco users (age 21  1 year; body mass index 27  1
g/m2). None of the subjects was taking any medication nor
ad any chronic disease. All subjects were asked to avoid
hewing or smoking tobacco for at least 12 h before each
tudy. The study was approved by the Mayo Clinic Insti-
utional Review Board.
easurements and procedures. Electrocardiogram was
ecorded continuously by EKG Bioamplifier (Gould Instru-
ent Systems, Valley View, Ohio). Blood pressure was
ecorded continuously (Finapres, Ohmeda, Englewood,
olorado) and also measured every minute (Dinamap,
ritikon Inc., Tampa, Florida). Calf blood flow was mea-
ured by venous occlusion plethysmography (14). Vascular
esistance was calculated by dividing mean arterial pressure
y flow and is expressed in arbitrary units. Multiunit
ostganglionic MSNA was recorded from the peroneal
erve with tungsten microelectrodes (15).
Blood samples were drawn at baseline during supine rest,
nd again after 30 min of tobacco chewing. Plasma nicotine
as determined using liquid chromatography tandem mass
pectrometry, with interassay variability of 20% at 2 ng/ml,
0% at 5 ng/ml, and 7% at 20 ng/ml. Plasma cat-
cholamines were measured using high-performance liquid
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March 15, 2005:910–4 Effects of Spit Tobaccohromatography (with interassay and intra-assay variability
f 3.4% and 3.1%, respectively).
tudy protocol. Subjects were studied in the supine posi-
ion. All measurements were obtained using a randomized,
ouble-blind, placebo-controlled, crossover design with two
xperimental sessions, a placebo session (Smokey Mountain
nuff, Smokey Mountain Chew Inc., Darien, Connecticut),
nd a tobacco session (Copenhagen moist tobacco snuff,
.S. Tobacco, Nashville, Tennessee). Smokey Mountain
nd Copenhagen snuff are commercially available tobacco
roducts that are similar in taste, texture, and color, except
hat Smokey Mountain snuff does not contain tobacco and
s nicotine-free. Each session was conducted using the same
rotocol on two separate days, in a random order.
Baseline measurements were obtained after 10 to 15 min
f rest. After the end of baseline recordings, the subjects
ere given orally 1.5 g of snuff tobacco/placebo for 15 min,
ollowed immediately by the second dose of tobacco/placebo
also 1.5 g), which was then kept in the mouth until the end
f the study. The second series of measurements was
erformed 30 min after the beginning of snuff administra-
ion, using exactly the same protocol as at baseline.
Hemodynamic and catecholamine data are reported for
6 subjects in whom measurements were obtained during
oth sessions. Stable MSNA signals of good technical
uality were obtained on both sessions in 10 subjects.
henylephrine infusion. Hemodynamic measures and
SNA were also recorded in a separate group of eight
ealthy subjects (6 males and 2 females; mean age 42  2
Abbreviations and Acronyms
BP  blood pressure
HR  heart rate
MSNA  muscle sympathetic nerve activity
able 1. Hemodynamic Parameters, MSNA, and Biochemical M
essions (n  16)
Placebo Session
Before Chewing After Che
emodynamics
SBP (mm Hg) 124  2 126  2
DBP (mm Hg) 57  2 60  1
MAP (mm Hg) 81  2 83  1
HR (beats/min) 57  1 57  1
PVR (U) 41  5 45  6
SNA (n  10) (bursts/min) 23  3 21  4
iochemical measurements
Nicotine (ng/ml) 2.6  0.6 2.7  0
Cotinine (ng/ml) 61  15 59  1
t-3-OH-cotinine (ng/ml) 39  10 37  9
Norepinephrine (pg/ml) 162  12 172  1
Epinephrine (pg/ml) 18  2 18  2
p  0.05, †p  0.01, ‡p  0.001 vs. respective baseline before chewing. The p valu
valuate time versus session interactions. The p values marked by symbols were obtaDBP  diastolic blood pressure; HR  heart rate; MAP  mean arterial pressure; MSN
systolic blood pressure.ears; two subjects were smokers) during phenylephrine
nfusion in the absence of snuff dipping, in order to mimic
he BP responses observed with acute spit tobacco exposure.
henylephrine was infused in progressively increasing doses
o achieve changes in BP similar to those observed after
nuff tobacco dipping in the main study cohort of spit
obacco users previously described.
tatistical analysis. Data were analyzed using two-way
nalysis of variance for repeated-measures with time (before
s. after snuff dipping) as the within factor and session
placebo vs. tobacco) as the between factor. Paired and
npaired (as appropriate) Student t tests were also used
or comparisons between groups with respect to the
hange () in a given variable. A value of p  0.05 was
onsidered statistically significant. Data are expressed as
ean  SEM.
ESULTS
emodynamic, MSNA, and biochemical measures before and
fter placebo and tobacco sessions are shown in Table 1. At
aseline, all variables were similar before the placebo and the
obacco sessions. Snuff tobacco dipping increased plasma nic-
tine (from 2.8 0.5 ng/ml to 10.4 1.1 ng/ml; p 0.001),
hereas levels remained stable during the placebo session
2.6 0.6 ng/ml vs. 2.7 0.6 ng/ml; pNS). Furthermore,
pit tobacco increased BP and HR (Fig. 1).
Despite the increased BP, both peripheral vascular resis-
ance (Fig. 1) and efferent sympathetic drive to peripheral
lood vessels (MSNA) (Fig. 2) were unchanged after
obacco administration. In contrast, a similar increase in BP
uring phenylephrine infusion (at a dose of 1.06  0.14
g/kg/min) in healthy subjects in the absence of snuff
obacco dipping caused a marked decrease in HR and
SNA (Figs. 3 and 4).
Plasma norepinephrine concentration remained un-
ements Before and After Placebo and Tobacco
Tobacco Session
Interaction
Time  Session
Before Chewing After Chewing p Value
122  2 134  2‡ 0.001
57  1 64  1‡ 0.001
79  1 90  1‡ 0.001
57  2 73  2‡ 0.001
44  7 44  6 0.364
23  3 20  2 0.768
2.8  0.5 10.4  1.1‡ 0.001
61  19 64  18† 0.001
43  19 44  20 0.212
164  17 180  26 0.758
15  2 23  4* 0.023
the table were obtained using two-way analysis of variance for repeated measures to
sing a paired t test to assess changes within each session.easur
wing
†
*
.6
5
0
es in
ined uA  muscle sympathetic nerve activity; PVR  peripheral vascular resistance; SBP
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Effects of Spit Tobacco March 15, 2005:910–4hanged after spit tobacco, but epinephrine levels increased
y about 50% (Fig. 2).
ISCUSSION
he novel findings of this study are first, that snuff tobacco
ipping causes an acute increase in HR and BP; second, that
espite the significant BP increase, norepinephrine, periph-
ral vascular resistance, and efferent sympathetic outflow to
uscle resistance vessels are not reduced by acute exposure
o spit tobacco; and third, that administration of spit
obacco is associated with a significant increase in plasma
pinephrine. These results suggest that the pressor effect of
pit tobacco results most likely from an increase in cardiac
utput. Consistent with this explanation is the observed
ncrease in HR.
Our results suggest the release of epinephrine from the
drenal gland in response to snuff tobacco. Indeed, nicotine
vokes catecholamine secretion in adrenal medulla cell
igure 1. Changes in systolic blood pressure (SBP), diastolic blood
ressure (DBP), mean arterial pressure (MAP), heart rate (HR), and
eripheral vascular resistance (PVR) during the placebo and tobacco
essions. *p  0.001. Despite a 10-mm Hg increase in blood pressure, HR
ncreased strikingly during tobacco use, with no change in PVR.
igure 2. Changes in muscle sympathetic nerve activity (MSNA), plasma
orepinephrine (Norepi), and epinephrine (Epi) during the placebo and
obacco sessions. Despite increased arterial pressure during tobacco uses
Fig. 1), there was no difference in MSNA or Norepi, but a clear increase
n Epi.ultures (16,17). In dogs whose adrenal glands had been
igated, the pressor response to nicotine was diminished
18). The observed increase in plasma epinephrine speaks to
he likelihood of preganglionic sympathetic excitation.
The acute increase in plasma epinephrine with spit
obacco may have implications for both intravascular throm-
osis and cardiac arrhythmias. Epinephrine is an important
latelet activator and is prothrombogenic; sudden surges in
pinephrine may trigger a hypercoagulable state and platelet
eposition in damaged arterial wall (19,20). Thus, smoke-
ess tobacco may possibly provide a stimulus for occlusive
rterial thrombosis. Epinephrine is also proarrhythmic in
nimal models and in humans (21); smokeless tobacco may
hus conceivably trigger cardiac arrhythmias in susceptible
ndividuals with an arrhythmogenic substrate. Risk for these
otential complications may be magnified in the context of
ignificant spit-tobacco-induced increases in BP and HR.
The absence of any significant inhibitory effect of spit
obacco on MSNA (consistent with the lack of any effect on
eripheral vascular resistance in the present study) supports
he concept of a sympathetic excitatory action of smokeless
obacco. Increasing BP by phenylephrine infusion, to the
evels noted after snuff tobacco dipping, activates the barore-
ex and elicits profound sympathetic inhibition (Figs. 3 and
), which would obscure any sympathetic excitatory effects
f smokeless tobacco. Therefore, the lack of suppression of
SNA and the increase in HR in the presence of elevated
P, together with the marked increase in epinephrine in
esponse to spit tobacco in our present study, speak further
o a potent, spit-tobacco-induced sympathetic excitation.
Several factors may help explain the increase in HR with
igure 3. Systolic blood pressure (SBP), heart rate (HR), and muscle
ympathetic nerve activity (MSNA) responses after snuff tobacco (n  10)
s compared to phenylephrine infusion (in the absence of chewing tobacco)
n  8). Heart rate increased during tobacco, but decreased with phenyl-
phrine. Despite increased blood pressure during tobacco, there was no
ignificant decrease in MSNA, although MSNA was virtually eliminated
uring phenylephrine. Faster HR and minimal MSNA suppression,
espite the similar blood pressures with spit tobacco use compared to
henylephrine, suggest a potent cardiac and vascular excitatory effect of spit
obacco, which overcomes the cardiac and sympathetic inhibitory influ-
nces of baroreflex activation in response to the rise in blood pressure.pit tobacco use despite the BP rise (which would be
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March 15, 2005:910–4 Effects of Spit Tobaccoxpected to elicit baroreflex-mediated bradycardia). These
nclude nicotine-induced activation of central sympathetic
utflow to the heart, and the tachycardic effects of nicotine-
igure 4. (A) Recordings of electrocardiogram (EKG), blood pressure (BP
fter spit tobacco. Despite increased BP with tobacco use, heart rate (HR
he same measurements at baseline and after raising blood pressure using
limination of MSNA because of baroreflex activation.nduced epinephrine release. Nicotine also has many indi- lect actions on the heart, including the release of cat-
cholamines from cardiac sympathetic nerve terminals (17).
tudy limitations. First, we studied the effects of smoke-
uscle sympathetic nerve activity (MSNA), and respiration at baseline and
ases, and MSNA is not suppressed. Contrast this with panel B showing
ylephrine. With phenylephrine, there is a slowing of HR and a complete), m
) incre
pheness tobacco only in habitual tobacco users, but we did not
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Effects of Spit Tobacco March 15, 2005:910–4nvestigate the effects of first acute exposure in nonusers.
evertheless, the practical applications of our results relate
rimarily to habitual users of smokeless tobacco.
Second, other mechanisms may explain some of the
emodynamic effects of smokeless tobacco, including high
odium content of smokeless tobacco products (which
iffers between different brands), as well as the presence of
harmacologically active ingredients other than nicotine
e.g., licorice) (22,23), not measured in the present study.
onclusions. Oral snuff tobacco leads to acute increases in
R, BP, and plasma epinephrine, in the absence of any
eduction of either MSNA or peripheral vascular resistance.
ncreased epinephrine levels suggest an important role for
atecholamine release from the adrenal medulla. These
bservations suggest that smokeless tobacco is a powerful
utonomic and hemodynamic stimulus, with potential im-
lications for cardiac and vascular risk.
eprint requests and correspondence: Dr. Virend K. Somers,
ayo Clinic, DO-4-350, 1216 Second Street SW, Rochester,
innesota 55902. E-mail: somers.virend@mayo.edu.
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